PUMCH Rare Disease Care: Multidisciplinary Teams and Diagnostic Review

A new department inside a long-established hospital

Peking Union Medical College Hospital (PUMCH) has a dedicated rare disease medicine department established in 2023. Its history of rare-disease work predates that organizational change. The department places joint clinical assessment, genetic interpretation, teaching and research within a platform intended for rare and undiagnosed illness, rather than presenting a single intervention for every difficult case.

The department page describes more than an outpatient room. It lists a joint clinic, a ward, genetic counselling and analysis, and a teaching platform, supported by a national rare-disease collaboration network, registry and quality-control centre. Read together, these describe an attempt to connect diagnosis, admission, genetic interpretation and shared learning rather than to route every patient through a single specialist.

For an overseas reader, the useful distinction is between the hospital's broader reputation and this specific department's remit. The department is the part of PUMCH explicitly organised around rare and undiagnosed disease. Whether a particular patient's problem fits that remit is a clinical judgement, and it is the first thing to clarify rather than assume.

What the department says it focuses on

The department’s published scope includes rare and undiagnosed disease, supported by a joint clinic and genetic counseling and analysis. The practical distinction is between asking a team to reassess an uncertain explanation and asking for treatment of an already established condition. Clarify which question remains unresolved and why a multidisciplinary opinion is being sought.

The director's specialist profile gives a sharper picture of one clinical direction. Shen Min, the department director, is a chief physician and doctoral supervisor whose stated expertise sits in rheumatology and immunology. Her profile highlights autoinflammatory diseases and inflammation-related primary immunodeficiency, alongside rheumatic autoimmune disease.

For an enquiry involving a suspected autoinflammatory or immune-deficiency condition, ask whether that is the appropriate disease direction for review and how the existing findings support or challenge it. Shen Min’s published expertise is a reason to frame that question carefully, not evidence that a symptom pattern establishes a diagnosis or that one assessment will resolve it.

The department roster also identifies Xu Jin as deputy director and Xie Jing as assistant and researcher. These are documented roles within the department. The page does not establish that every listed person takes separate outside bookings, so a patient should not treat a name on a roster as a confirmed appointment route.

Why multidisciplinary review is the organising idea

Rare and undiagnosed illness often fails to fit one specialty. A child with widespread calcification and multisystem involvement may generate imaging, pathology, metabolic and genetic questions at once. A hospital report dated 19 August 2026 describes exactly this kind of joint review, requested by Beijing Children's Hospital, in which specialists compared those strands of evidence.

The same report is careful about what the review achieved. It states that important diagnostic questions remain and that continuing evaluation is planned. That is the honest shape of much rare-disease work: a multidisciplinary meeting can narrow possibilities, reframe the problem and decide what evidence is still missing without producing a final answer on the day.

This is why the department's structure matters more than any single consultation. The joint clinic, the ward and the genetic analysis function are designed to let several perspectives examine the same records. For a patient, the practical implication is that the value of review depends heavily on what records exist and how they are organised before the discussion happens.

The research and quality-control infrastructure behind the clinic

PUMCH's research overview identifies a state key laboratory for difficult, severe and rare diseases, approved for construction in 2020, alongside translational medicine and other platforms. This is institutional infrastructure. It tells a reader that rare disease work at the hospital is connected to a formal research environment, not that every patient will encounter a research protocol or a novel treatment.

A PUMCH report dated 27 July 2026 documents rare-disease teaching coordinated by national and Beijing quality-control centres. In that dated report, Zhang Shuyang is described as hospital president and director of those centres, while Shen Min chairs the course. The content covered multisystem cases, genetics, clinical research and multidisciplinary team observation.

Two clarifications follow. First, Zhang Shuyang's role as hospital and quality-control leader is a different post from Shen Min's department director role; they should not be conflated. Second, a teaching and quality-control programme is a network and education activity. It does not establish that a particular overseas patient can obtain an English-language service, an immediate multidisciplinary meeting or a place in any study.

Team recognition and historical specialty reputation

Shen Min's official profile lists membership of a National Huang Danian-style Teaching Team and a first-contributor PUMCH Medical Research Achievement Second Prize. The profile does not give dates for these, so they should be read as undated statements on the checked page rather than as recent awards.

Both are best understood as team and institutional recognitions. The teaching-team membership is a collective honour, and the research prize is a hospital-level award in which she is listed as first contributor. Neither is a national science prize awarded to her personally, and neither should be converted into a promise about an individual patient's outcome.

PUMCH was first in the 2023 Fudan national rare-disease specialty reputation list. This is a dated specialty reference, not a ranking of individual clinicians or of the hospital’s disease-specific teams.

Practical decisions for an overseas patient

First, ask whether a rare-disease or undiagnosed-disease review fits the actual problem. Explain the current working diagnosis, the opinions already obtained and the point on which they differ. If one organ-specific issue dominates, ask whether the relevant specialty should lead the assessment and how other teams would contribute, rather than assume every complicated condition needs the same route.

Second, ask which existing records would help answer that question. Depending on the problem, the discussion may concern longitudinal imaging, pathology, metabolic findings, genetic reports or a chronology of symptoms and treatment. The receiving team should specify what it needs, in which format and language, and whether original slides or images are necessary. This is not a fixed investigation checklist for every patient.

The third decision is about expectations. A review can reframe a diagnosis, identify a missing test or confirm that a question remains open. It does not guarantee a name for the condition, and many rare diseases still lack a known cause or an effective cure. Patients should ask, in advance, what the clinicians understand the main unresolved question to be.

The fourth decision is administrative and should be asked rather than assumed. Does the hospital require referral from the patient's own physician? Which department triages rare-disease enquiries? Is interpretation needed for the clinical discussion, and who arranges it? What is the expected sequence between records review and any in-person visit? These are provider-specific questions, and the answers should come from the hospital or a coordinator acting on confirmed information.

Rare disease assessment and care planning

Where independent coordination fits

ChinaSpecialistCare can organise a rare-disease assessment request and help present the existing evidence and unresolved questions clearly. We provide independent, non-clinical coordination, not hospital representation. The hospital decides acceptance, the reviewing disciplines and clinical suitability; a diagnosis, experimental treatment, named expert or immediate multidisciplinary meeting cannot be promised.